The mammalian target of rapamycin inhibitors in breast cancer: Current evidence and future directions

Paola Malaguti, Sabrina Vari, Francesco Cognetti, Alessandra Fabi

Research output: Contribution to journalArticle

Abstract

Mammalian target of rapamycin (mTOR) is a crucial mediator of tumor progression and may be a promising target in a significant proportion of patients with breast cancer. More specifically, the phosphatidylinositol-3- kinase (PI3K)/protein kinase B (AKT)/mTOR pathway plays a critical role in multiple cellular functions including metabolism, proliferation, growth and survival. This pathway is higly active in many types of cancer and is linked to resistance to many types of therapy. Direct blockade of the mTOR pathway is a new area in breast cancer therapy, with the potential to modulate growth factor- and estrogendependent and estrogen-independent pathways, which contribute to the pathogenesis and progression of tumors. Thus, inhibitors of mTOR are of interest as potential therapeutic agents for patients with breast cancer, everolimus and temsirolimus being the main representatives of this category. This review of the literature analyzes the available data emerging from trials and evaluates the efficacy and safety of mTOR inhibitors in all subtypes of breast cancer.

Original languageEnglish
Pages (from-to)21-28
Number of pages8
JournalAnticancer Research
Volume33
Issue number1
Publication statusPublished - Jan 2013

Fingerprint

Sirolimus
Breast Neoplasms
Phosphatidylinositol 3-Kinase
Neoplasms
Proto-Oncogene Proteins c-akt
Proxy
Intercellular Signaling Peptides and Proteins
Estrogens
Therapeutics
Direction compound
Safety
Survival
Growth

Keywords

  • AKT
  • Breast cancer
  • Endocrine resistance
  • Everolimus
  • MTOR inhibitor
  • PI3K
  • Review
  • Temsirolimus

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The mammalian target of rapamycin inhibitors in breast cancer : Current evidence and future directions. / Malaguti, Paola; Vari, Sabrina; Cognetti, Francesco; Fabi, Alessandra.

In: Anticancer Research, Vol. 33, No. 1, 01.2013, p. 21-28.

Research output: Contribution to journalArticle

@article{de35385c161e4089ba03559e003ed994,
title = "The mammalian target of rapamycin inhibitors in breast cancer: Current evidence and future directions",
abstract = "Mammalian target of rapamycin (mTOR) is a crucial mediator of tumor progression and may be a promising target in a significant proportion of patients with breast cancer. More specifically, the phosphatidylinositol-3- kinase (PI3K)/protein kinase B (AKT)/mTOR pathway plays a critical role in multiple cellular functions including metabolism, proliferation, growth and survival. This pathway is higly active in many types of cancer and is linked to resistance to many types of therapy. Direct blockade of the mTOR pathway is a new area in breast cancer therapy, with the potential to modulate growth factor- and estrogendependent and estrogen-independent pathways, which contribute to the pathogenesis and progression of tumors. Thus, inhibitors of mTOR are of interest as potential therapeutic agents for patients with breast cancer, everolimus and temsirolimus being the main representatives of this category. This review of the literature analyzes the available data emerging from trials and evaluates the efficacy and safety of mTOR inhibitors in all subtypes of breast cancer.",
keywords = "AKT, Breast cancer, Endocrine resistance, Everolimus, MTOR inhibitor, PI3K, Review, Temsirolimus",
author = "Paola Malaguti and Sabrina Vari and Francesco Cognetti and Alessandra Fabi",
year = "2013",
month = "1",
language = "English",
volume = "33",
pages = "21--28",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1",

}

TY - JOUR

T1 - The mammalian target of rapamycin inhibitors in breast cancer

T2 - Current evidence and future directions

AU - Malaguti, Paola

AU - Vari, Sabrina

AU - Cognetti, Francesco

AU - Fabi, Alessandra

PY - 2013/1

Y1 - 2013/1

N2 - Mammalian target of rapamycin (mTOR) is a crucial mediator of tumor progression and may be a promising target in a significant proportion of patients with breast cancer. More specifically, the phosphatidylinositol-3- kinase (PI3K)/protein kinase B (AKT)/mTOR pathway plays a critical role in multiple cellular functions including metabolism, proliferation, growth and survival. This pathway is higly active in many types of cancer and is linked to resistance to many types of therapy. Direct blockade of the mTOR pathway is a new area in breast cancer therapy, with the potential to modulate growth factor- and estrogendependent and estrogen-independent pathways, which contribute to the pathogenesis and progression of tumors. Thus, inhibitors of mTOR are of interest as potential therapeutic agents for patients with breast cancer, everolimus and temsirolimus being the main representatives of this category. This review of the literature analyzes the available data emerging from trials and evaluates the efficacy and safety of mTOR inhibitors in all subtypes of breast cancer.

AB - Mammalian target of rapamycin (mTOR) is a crucial mediator of tumor progression and may be a promising target in a significant proportion of patients with breast cancer. More specifically, the phosphatidylinositol-3- kinase (PI3K)/protein kinase B (AKT)/mTOR pathway plays a critical role in multiple cellular functions including metabolism, proliferation, growth and survival. This pathway is higly active in many types of cancer and is linked to resistance to many types of therapy. Direct blockade of the mTOR pathway is a new area in breast cancer therapy, with the potential to modulate growth factor- and estrogendependent and estrogen-independent pathways, which contribute to the pathogenesis and progression of tumors. Thus, inhibitors of mTOR are of interest as potential therapeutic agents for patients with breast cancer, everolimus and temsirolimus being the main representatives of this category. This review of the literature analyzes the available data emerging from trials and evaluates the efficacy and safety of mTOR inhibitors in all subtypes of breast cancer.

KW - AKT

KW - Breast cancer

KW - Endocrine resistance

KW - Everolimus

KW - MTOR inhibitor

KW - PI3K

KW - Review

KW - Temsirolimus

UR - http://www.scopus.com/inward/record.url?scp=84873021780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873021780&partnerID=8YFLogxK

M3 - Article

C2 - 23267124

AN - SCOPUS:84873021780

VL - 33

SP - 21

EP - 28

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1

ER -